Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Liver lesions shrank after treatment with octreotide and Lutetium-177 vipivotide tetraxetan...The role of microsatellite instability (MSI) as a screening marker, and personalized treatment approaches like immunotherapy for dMMR tumors. Understanding these correlations may assist in early discovery, surveillance, and customized treatment for patients dealing with LS-associated malignancies.

P4, N=20, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

P=N/A, N=1067, Not yet recruiting, Novartis Pharmaceuticals

P2, N=60, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Apr 2033 --> Jul 2033 | Initiation date: Apr 2026 --> Jul 2026 | Trial primary completion date: Apr 2032 --> Jul 2032

P2, N=162, Active, not recruiting, Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Trial completion date: Jan 2025 --> Dec 2026

P2, N=202, Not yet recruiting, Mayo Clinic

P3, N=1524, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Mar 2026

P2, N=23, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026

Their natural origin and established safety profile underscore their translational potential. Thus, genistein and baicalein represent promising novel adjuvants for prostate cancer radioligand therapy.

P1, N=42, Recruiting, Weill Medical College of Cornell University | N=20 --> 42 | Active, not recruiting --> Recruiting

In this pilot cohort, concomitant ARSi therapy did not significantly enhance tumor absorbed doses in patients receiving [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T RLT. Further prospective studies with larger patient numbers are needed to evaluate the impact of concomitant ARSi treatment on the absorbed doses in mCRPC tumor lesions.

In a head-to-head comparison with clinically approved 177Lu-PSMA-617 (Pluvicto), PSMA-targeted TRT@LnOMVs achieved a 90% survival rate in a prostate cancer model, far surpassing the 25% survival rate of Pluvicto...This occurred through reprogramming immunosuppressive myeloid compartments (including neutrophil subsets and macrophages), expanding cytotoxic CD8+ T and NK cell infiltration, and activating innate immunity to trigger robust antitumor responses. Collectively, TRT@LnOMVs represent a versatile class of biohybrid therapeutics, offering a robust paradigm for next-generation radio-immunotherapy.